All In Biotech

Drug Trial Radar · NCT03025789

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

Nov 10, 2016

Primary completion

Feb 1, 2021

Study completion Feb 1, 2021

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi
First posted
Jan 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the effectiveness of fexinidazole administered to patients with human African trypanosomiasis due to T. b. gambiense (g-HAT) at all stages of the disease. The aim of the present study is to provide additional information on the effectiveness and safety of fexinidazole and to assess its use under conditions as close as possible to those in real life, both in patients treated on an out-patient basis and in the hospital setting, depending on clinical status. Participants will receive fexinidazole oral treatment for 10 days. Regular blood draws and lumbar punctures will be performed over 18 months to confirm the cure of the disease. Other assessments will include the recording of adverse events, signs and symptoms of the disease, laboratory tests, vital signs, electrocardiograms. Treatment compliance, feasibility, and packaging acceptability will be thoroughly assessed in the participants receiving treatment at home. Those participants will complete questionnaires to check that instructions for fexinidazole administration are clear enough and followed correctly.

Conditions

  • Trypanosomiasis, African
  • Sleeping Sickness
  • Trypanosomiasis; Gambian

Interventions

  • FexinidazoleDrug

    Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Whose Treatment Outcome at Month 18 is a SuccessTime frame: Between the first intake of fexinidazole (Day 1) and the end of the follow-up period (18 months)

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Roi Baudouin Hospital

    Kinshasa, Democratic Republic of the Congo

  • Dipumba Hospital

    Mbuji-Mayi, Kasaï Oriental Province, Democratic Republic of the Congo

  • Bagata Hospital

    Bagata, Kwilu, Democratic Republic of the Congo

  • Bandundu Hospital

    Bandundu Province, Kwilu, Democratic Republic of the Congo

  • Masi Manimba Hospital

    Masi-Manimba, Kwilu, Democratic Republic of the Congo

  • Nkara Secondary Hospital

    Nkara, Kwilu, Democratic Republic of the Congo

  • Mushie Hospital

    Mushie, Maï Ndombe Province, Democratic Republic of the Congo

  • Dubreka Hospital

    Dubréka, Guinea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.